Department of Obstetrics, Gynecology and Reproductive Health, Rutgers New Jersey Medical School, Newark, NJ.
Envision Sexual and Reproductive Health, Los Angeles, CA.
J Low Genit Tract Dis. 2021 Jul 1;25(3):187-191. doi: 10.1097/LGT.0000000000000614.
The American Cancer Society (ACS) released updated cervical cancer screening guidelines in 2020 that endorse a shift in practice to primary human papillomavirus (HPV) screening in people with a cervix, beginning at ages of 25-65 years. When access to US Food and Drug Administration-approved primary HPV testing is not available, the ACS offers cotesting or cytology as acceptable alternative strategies but suggests that these testing modalities may be excluded from future iterations of the guidelines. The ASCCP recognizes the benefits and risks of primary HPV cervical cancer screening while acknowledging the barriers to widespread adoption, including implementation issues, the impact of limited HPV vaccination in the United States, and inclusion of populations who may not be well represented on primary HPV screening trials, such as underrepresented minorities. The ASCCP endorses the 2018 US Preventive Services Task Force Recommendation Statement and supports the ACS cervical cancer screening guidelines. Most importantly, the ASCCP endorses any cervical cancer screening for secondary prevention of cervical cancer and recommends interventions that improve screening for those who are underscreened or unscreened.
美国癌症协会（ACS）在 2020 年发布了更新的宫颈癌筛查指南，支持在有子宫颈的人群中进行主要人乳头瘤病毒（HPV）筛查的做法转变，起始年龄为 25-65 岁。当无法获得美国食品和药物管理局批准的主要 HPV 检测时，ACS 提供联合检测或细胞学检测作为可接受的替代策略，但建议这些检测方式可能会从指南的未来迭代中排除。ASCCP 认识到主要 HPV 宫颈癌筛查的益处和风险，同时承认广泛采用的障碍，包括实施问题、美国 HPV 疫苗接种的有限影响，以及可能无法在主要 HPV 筛查试验中得到充分代表的人群，如代表性不足的少数族裔。ASCCP 认可 2018 年美国预防服务工作组推荐声明，并支持 ACS 的宫颈癌筛查指南。最重要的是，ASCCP 支持任何用于宫颈癌二级预防的宫颈癌筛查，并建议采取干预措施，改善对那些未接受过或未接受过筛查的人的筛查。
